Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCI-NRG ALK Protocol in Previously Treated ALK-Positive Non-Squamous NSCLC
NCT03737994Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Fragment-Derived Small Molecules, Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib, brigatinib, alectinib, ceritinib, ensartinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by National Cancer Institute. Started Jul 2019; status: terminated.
02
Drugs
lorlatinibbrigatinibalectinibceritinibensartinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03737994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737994.